Medical/Pharmaceuticals
Next Generation Refractive Surgery to LASIK and SMILE Now Available for Clinical Review
Pioneer surgeon Dr Natasha Lim is among the first in Singapore to offer Smooth Incision Lenticular Keratomileusis (SILK) procedure in their clinics. SINGAPORE, Aug. 18, 2025 /PRNewswire/ -- Dr. Natasha Lim, an internationally renowned surgeon in Ophthalmology, has introduced an alternative to est...
2025-08-18 11:00
1732
New support group to provide social and community support for neurofibromatosis patients
Co-founded by individuals living with this rare genetic condition, the Neurofibromatosis Society Singapore seeks to close gaps in mental and emotional care SINGAPORE, Aug. 18, 2025 /PRNewswire/ -- A new patient-led support group, the Neurofibromatosis Society (NFS)Singapore, has been recently re...
2025-08-18 09:00
1791
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Shanghai, Aug. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that etrasimod (VELSIPITY®) has be...
2025-08-15 09:35
2113
TraceLink Accelerates Supply Chain Transformation with New OPUS Platform Capabilities for an AI-Powered Future
BOSTON, Aug. 14, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, today announced significant new platform enhancements to drive supply chain transformation with itsOrchestration Platfor...
2025-08-14 22:00
1887
Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma
NANJING, China, Aug. 14, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LB...
2025-08-14 17:38
2191
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Taiwan Food and Drug Adminis...
2025-08-14 12:02
2121
Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
* Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) * NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irr...
2025-08-14 08:00
1940
The Rainwater Charitable Foundation, Aging Mind Foundation, Alzheimer's Association, and CurePSP Join Forces to Award $2.5 Million in Neurodegenerative Disease Research Grants from 2025 Tauopathy Challenge Workshop
Established in 2023, the Tauopathy Challenge Workshop aims to bridge the gap in funding of novel neurodegenerative research for primary tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs). FORT WORTH, Texas, Aug. 13, 2...
2025-08-13 20:00
1986
New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection System in Comprehensive Protection for the Entire Interventional Team
MINNEAPOLIS, Aug. 13, 2025 /PRNewswire/ -- A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest™ Complete radiation shielding system, demonstrating its superior ability to protect all personnel in...
2025-08-13 19:30
1557
Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China
YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren's syndr...
2025-08-13 17:57
1805
Avive Health to host Queensland's first Empax clinic in landmark mental health partnership with Emyria
BRISBANE, Australia, Aug. 13, 2025 /PRNewswire/ -- Avive Health ("Avive"), an Australian-owned private mental health provider, has announced a major national partnership with Emyria Limited (ASX: EMD), marking a significant milestone in the evolution of evidence-based, reimbursable mental heal...
2025-08-13 15:40
2208
Prince Court Medical Centre Strengthens Malaysia's Position as a Global Healthcare Destination with First Kelly Procedure
KUALA LUMPUR, Malaysia, Aug. 13, 2025 /PRNewswire/ -- Prince Court Medical
Centre has placedMalaysia firmly on the global medical tourism map by
successfully performing the country's first Kelly procedure, an advanced
reconstructive surgery for rare congenital urological conditions.
2025-08-13 15:16
2004
KBP's Contest of Injunction Obtained by Novo Nordisk Continues in Arbitration
SINGAPORE, Aug. 13, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company ") today issued a statement addressing a further decision by the Singapore International Commercial Court (the "Court") to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr....
2025-08-13 09:44
4494
Manipal Hospitals Kolkata completes 50 successful TAVR cases
KOLKATA, India, Aug. 12, 2025 /PRNewswire/ -- Manipal Hospitals - EM Bypass (erstwhile Medica Superspecialty Hospital),Kolkata is thrilled to announce the completion of50 successful Transcatheter Aortic Valve Replacement (TAVR) cases, establishing the facility as a regional market leader in struc...
2025-08-12 17:29
1512
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
* Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale. This advancement integrates industry-leading technologies,...
2025-08-12 17:00
1989
Intas & Accord signs Agreement to acquire Prothya Biosolutions
AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based...
2025-08-11 21:41
2702
Caliber Enters 25th Year of Empowering Global Pharma with GxP Digital Solutions
HYDERABAD, India, Aug. 11, 2025 /PRNewswire/ -- Caliber, a leading global
provider of GxP-compliant digital solutions for the life sciences industry,
proudly announces the start of its 25th year of operations.
2025-08-11 21:22
2859
REVEALING STUDY HAS REJUVANT LEADING THE LONGEVITY PACK
Renowned Longevity Researcher Reveals Highlights of New Study to NBJ Conference Guests FERNANDINA BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- Dr. Brian Kennedy, one of the world's leading Longevity researchers, gave a keynote presentation at the Nutritional Business Journal's annual CEO conferenc...
2025-08-11 20:06
1583
Everest Medicines to Announce 2025 Interim Results on August 29, 2025
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim resul...
2025-08-11 17:11
1895
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
* WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. * WuXia293Stable platform maintains stable expression and consistent product quality during long-term c...
2025-08-11 16:30
1916
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 314 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
GIGABYTE Strengthens NVIDIA® Partnership to Drive Innovation in AI-Powered Gaming and Creative Solutions
2026-01-17 00:00
7212
GAC Energy Releases 2025 EV Charging Ecosystem Report: Over 23,000 Self-Operated Charging Piles Across China
2026-01-17 10:59
5788
